Featured Research

from universities, journals, and other organizations

New hope for PAD sufferers

Date:
May 2, 2012
Source:
Dartmouth-Hitchcock Medical Center
Summary:
Research by vascular surgeons may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells.

Research led by vascular surgeons at Dartmouth-Hitchcock may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells.

Richard J. Powell MD, chief of vascular surgery at Dartmouth-Hitchcock, is the principal investigator on a national study -- involving 550 patients at 80 sites around the country -- of so-called "no option" patients, for whom the disease is so advanced that amputation is the only available treatment.

Powell's study is now in a three-year, third-stage clinical trial, after second-stage trials showed remarkable success at treating patients with CLI. The final results of the second-stage clinical trial have been published in the April, 2012, issue of Molecular Therapy.

Peripheral artery disease (PAD) afflicts more than 9 million patients in the United States. The condition results from blockages in blood vessels caused by atherosclerosis -- hardening of the arteries -- which can be a consequence of diabetes, high cholesterol, smoking, genetic predisposition, and other circumstances. In many cases, endovascular therapies such as insertion of stents or bypass surgery -- similar to surgical processes used to treat blockages in the arteries of the heart -- are used to reintroduce blood flow to the legs. But in about 150,000 patients with the most-severe forms of PAD, called critical limb ischemia or CLI, the disease is so extensive that endovascular therapy isn't an option. That's where Powell's stem cell study comes in.

"All of us have stem cells in our bone marrow, and these stem cells can be utilized to repair other parts of our bodies," says Powell. "By taking the patient's own stem cells and injecting them into the ischemic leg, our hope is that we will then improve the blood flow in that part of the leg."

In the study, bone marrow is removed from the patient's hip, and then sent to a lab where stem cells are separated from the marrow and incubated over a two-week period, allowing more stem cells to grow. The stem cells are then re-injected intramuscularly into about 20 different spots on the patient's leg.

"We found that patients who received the stem cell therapy had a significantly lower incidence of amputation at six months than patients who received a placebo," said Powell.

After six months of the second-stage trials, approximately half of the patients who received a placebo died, required an amputation or saw their leg wounds worsen. Of those receiving the stem cell therapy, only a quarter died, required amputation, or saw their wounds worsen. Many showed significant improvement in blood flow in the ischemic limb.

"What was truly remarkable was that it was a relatively small number of patients, but that we saw clinically significant improvement in the stem cell-treated patients," he says. "It's compelling enough that there's no question that the pivotal trial needs to be done as quickly as possible."

The phase three trial has just begun, in which half of the patients will receive stem cell therapy and half will receive the placebo, measuring incidents of amputation or death one year after the treatment "We really want to see a therapy that's effective out to a year," says Powell. "Nonetheless, the results so far are really promising."


Story Source:

The above story is based on materials provided by Dartmouth-Hitchcock Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard J Powell, William A Marston, Scott A Berceli, Raul Guzman, Timothy D Henry, Amy T Longcore, Theresa P Stern, Sharon Watling, Ronnda L Bartel. Cellular Therapy With Ixmyelocel-T to Treat Critical Limb Ischemia: The Randomized, Double-blind, Placebo-controlled RESTORE-CLI Trial. Molecular Therapy, 2012; DOI: 10.1038/mt.2012.52

Cite This Page:

Dartmouth-Hitchcock Medical Center. "New hope for PAD sufferers." ScienceDaily. ScienceDaily, 2 May 2012. <www.sciencedaily.com/releases/2012/05/120502112711.htm>.
Dartmouth-Hitchcock Medical Center. (2012, May 2). New hope for PAD sufferers. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/05/120502112711.htm
Dartmouth-Hitchcock Medical Center. "New hope for PAD sufferers." ScienceDaily. www.sciencedaily.com/releases/2012/05/120502112711.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins